Release date: 2007-11-05
Recent advancements in the study of collateral diseases have gained significant attention in both China and the global medical community. At the 3rd International Conference on Collateral Diseases, Professor Wu Yiling, a leading scientist from the National 973 Program, delivered a keynote speech on the foundational theories of vascular disease guided by the concept of collateral diseases. The presentation attracted widespread interest not only from researchers across China but also from experts in the U.S. and South Korea. Over 800 scholars from India and other countries attended, showing great enthusiasm and appreciation for the research. This development marks another milestone in the field of collaterals research, following the "Second Prize for National Science and Technology Progress" awarded to Professor Wu Yiling earlier this year.
Collateral disease refers to a complex pathological condition commonly seen in chronic and refractory conditions such as cardiovascular diseases, cerebrovascular diseases, and diabetic vascular complications. It has become a key focus in national basic research. Currently, more than 20 universities, including Peking University, Zhongshan University, and Xiamen University, offer courses on collateral diseases. Additionally, Harvard Medical School includes it as part of its continuing education programs for physicians.
Professor Wu Yiling has dedicated over two decades to the theoretical study of collateral diseases. He proposed the "three-dimensional network system" framework for understanding these conditions. His work has led to significant progress in applying collateral disease theory to the prevention and treatment of vascular lesions. As a result, several effective traditional Chinese medicine treatments have been developed, including Tongxinluo Capsule for coronary heart disease, Shensong Yangxin Capsule for arrhythmia, and Qiqiangxin Capsule for chronic heart failure. These drugs represent a new generation of therapies in the treatment of cardiovascular and cerebrovascular diseases. Among them, Tongxinluo Capsule was honored with the Second Prize for National Science and Technology Progress.
Today, extensive research and clinical trials on Tongxinluo are being conducted throughout China. According to incomplete data, over 1,000 research papers on Tongxinluo have been published in biomedical journals worldwide. These studies reflect the scientific validation of the collateral disease theory and highlight the technological value of traditional Chinese medicine in addressing complex vascular conditions.
— China Medicine 123 Network
Autoclavable cleanroom coverall,Disposable cleanroom garment,Cleanroom Coverall with hood,Cleanroom Coverall with Undergarment
AUSTAR Goup , https://www.hansencleanroom.com